The American Pharmacists Association (APhA), in its efforts to uphold high standards of practicing nuclear pharmacy, has announced a series of educational sessions that will focus on nuclear pharmacy at its 2016 APhA Annual Meeting and Exposition Read More »
The American Pharmacists Association (APhA) announced this week that it has unveiled a new resource center in its continuing fight against prescription drug and opioid abuse that will provide pharmacists with more information pertaining to opioid use, abuse and misuse. Read More »
Astellas Pharma Inc. announced earlier this week that is has obtained approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug application (sNDA) for its product Kiklin capsules 250mg. Read More »
Earlier this week, the National Association of Chain Drug Stores (NACDS) issued a letter to members of the U.S. Senate to try and convince them to pass a legislation that would push for health care and enforcement authorities to work together for a solution to the prescription drug abuse problem in order to uphold patients’ legitimate access to medicines. Read More »
Prime Therapeutics LLC, a company that manages pharmacy benefits and serves more than 26 million people, recently named Jonathan B. Gavras, M.D., as its new chief medical officer (CMO). Read More »
AstraZeneca has announced it has completed an agreement that will transfer the rights of Moventig (naloxegol) to Kyowa Hakko Kirin subsidiary, ProStrakan Group. Read More »
Endocare Inc. has announced it has signed an exclusive agreement with R-Action Distribution Sarl, which is a subsidiary of R-Action SAS, that will allow the distribution of its Endocare Cryoablation technology in France and Switzerland. Read More »
AstraZeneca announced this week that it has agreed to the terms of a licensing agreement with China Medical System Holdings Ltd. (CMS) that will give CMS commercialization rights for Plendil (felodipine) in China. Read More »
Generic Pharmaceutical Association (GPhA) CEO and President Chip Davis stated in a recent press release that generic drug savings were imperative to long-term solutions to rising health costs and explained that the focus should be on increasing pharmaceutical competition and expanding access to safe, effective and more affordable generic drugs. Read More »
Aldeyra Therapeutics Inc. has reported that its Phase 2a clinical trial of topical ocular NS2 has shown positive results. Read More »
GenSight Biologics S.A. announced this week that the first patient has enrolled in the company’s two parallel Phase 3 trials for GS010, a medicine designed to treat Leber’s Hereditary Optic Neuropathy (LHON). Read More »
Dan Durham, the EVP for Health Policy of the Biotechnology Innovation Organization (BIO), has released a statement in response to the White House’s announcement about its intent to fast-track the Precision Medicine Initiative. Read More »
CVS Health announced last week that its EVP and CFO, Dave Denton, will address investors at the Cowen and Co. 36th Annual Health Care Conference. Read More »
Curexa Pharmacy has received full accreditation status from the Utilization Review Accreditation Commission (URAC) due to its specialty pharmacy services. Read More »
The U.S. Food and Drug Administration (FDA) has approved Allegran’s prescription topical acne treatment for patients ages 12 and over, ACZONE Gel, 7.5%. Read More »
McKesson Corp. announced this week that it has agreed to terms to buy Vantage Oncology LLC and Biologics Inc. Read More »
Baxalta Inc., a worldwide leader in pharmaceuticals committed to developing therapies to combat orphan diseases, has announced the submission of supplemental Biologics License Applications (sBLAs) for the approval of ADYNOVATE by the U.S. Food and Drug Administration (FDA). Read More »
An estimated 3 percent of the world’s population struggles with the Hepatitis C virus (HCV), and rates have increased since the turn of the century. Read More »
The CVS Health Foundation announced this week that it has donated $550,000 to the Alzheimer’s Association. Read More »
Allegran announced this week that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for AVYCAZ and has granted the sNDA priority review status. Read More »
Alerts Sign-up
